II期试验-话题@MedSci

#II期试验#

98篇内容 | 2740人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1947744, encodeId=4d07194e7441c, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=Novavax启动COVID-19候选疫苗NVX-CoV2373的I / II期试验, objectType=article, longId=194739, objectId=c5e8194e39ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5e8194e39ed, replyNumber=0, likeNumber=66, createdTime=2020-07-30, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5e8194e39ed, moduleTitle=Novavax启动COVID-19候选疫苗NVX-CoV2373的I / II期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c5e8194e39ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947739, encodeId=9d21194e739b1, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=ACE-083治疗夏科-马里-图思病（CMT）的II期试验遭遇滑铁卢, objectType=article, longId=189676, objectId=19c21896e64e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19c21896e64e, replyNumber=0, likeNumber=107, createdTime=2020-04-21, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19c21896e64e, moduleTitle=ACE-083治疗夏科-马里-图思病（CMT）的II期试验遭遇滑铁卢, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19c21896e64e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947740, encodeId=7671194e740c0, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=VEGFR抑制剂Cediranib联合PARP抑制剂Lynparza治疗铂敏感复发性卵巢癌的III期试验失败, objectType=article, longId=190019, objectId=8870190019fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8870190019fe, replyNumber=0, likeNumber=79, createdTime=2020-08-31, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8870190019fe, moduleTitle=VEGFR抑制剂Cediranib联合PARP抑制剂Lynparza治疗铂敏感复发性卵巢癌的III期试验失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8870190019fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947733, encodeId=0677194e733c3, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=ChemoCentryx的Avacopan补体5a受体抑制剂治疗血管炎的III期试验达到了主要终点, objectType=article, longId=183997, objectId=f31218399ec7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f31218399ec7, replyNumber=0, likeNumber=95, createdTime=2020-01-30, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f31218399ec7, moduleTitle=ChemoCentryx的Avacopan补体5a受体抑制剂治疗血管炎的III期试验达到了主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f31218399ec7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947738, encodeId=0b86194e73844, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=2020年ASCO-SITC：Ilixadencel治疗肾癌的II期试验的数据更新, objectType=article, longId=187678, objectId=a86418e6787e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a86418e6787e, replyNumber=0, likeNumber=98, createdTime=2021-01-15, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a86418e6787e, moduleTitle=2020年ASCO-SITC：Ilixadencel治疗肾癌的II期试验的数据更新, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a86418e6787e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947726, encodeId=8f2b194e72627, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=诺华的CD20单抗Arzerra治疗多发性硬化症的两项III期试验成功, objectType=article, longId=178542, objectId=bc501e854207, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc501e854207, replyNumber=0, likeNumber=162, createdTime=2020-04-07, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc501e854207, moduleTitle=诺华的CD20单抗Arzerra治疗多发性硬化症的两项III期试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc501e854207)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947729, encodeId=1491194e7295e, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=Biogen的aducanumab治疗阿尔茨海默氏病符合III期试验终点, objectType=article, longId=181870, objectId=66f71818e0a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66f71818e0a7, replyNumber=0, likeNumber=86, createdTime=2019-12-17, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66f71818e0a7, moduleTitle=Biogen的aducanumab治疗阿尔茨海默氏病符合III期试验终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66f71818e0a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947732, encodeId=12bc194e73251, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=第68届ASTMH年会：登革热候选疫苗关键III期试验的18个月数据, objectType=article, longId=183562, objectId=963318356294, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=963318356294, replyNumber=0, likeNumber=69, createdTime=2020-07-05, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=963318356294, moduleTitle=第68届ASTMH年会：登革热候选疫苗关键III期试验的18个月数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=963318356294)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947735, encodeId=ec74194e7351f, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=J Clin Oncol：III期试验：培美曲塞联合贝伐单抗作为NSCLC患者的维持疗法的有效性和安全性, objectType=article, longId=185701, objectId=ca92185e013a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca92185e013a, replyNumber=0, likeNumber=81, createdTime=2020-01-26, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca92185e013a, moduleTitle=J Clin Oncol：III期试验：培美曲塞联合贝伐单抗作为NSCLC患者的维持疗法的有效性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ca92185e013a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947723, encodeId=05f8194e7237e, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=Rivipansel治疗镰状细胞病的III期试验：未达到主要终点, objectType=article, longId=176941, objectId=47371e6941f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47371e6941f2, replyNumber=0, likeNumber=63, createdTime=2019-09-27, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47371e6941f2, moduleTitle=Rivipansel治疗镰状细胞病的III期试验：未达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47371e6941f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947731, encodeId=0262194e731c7, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=2019 ESMO亚洲大会：国产曲妥珠单抗仿制药HLX02治疗乳腺癌在全球III期试验达到了主要终点, objectType=article, longId=183554, objectId=f33d18355468, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f33d18355468, replyNumber=0, likeNumber=79, createdTime=2020-06-02, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f33d18355468, moduleTitle=2019 ESMO亚洲大会：国产曲妥珠单抗仿制药HLX02治疗乳腺癌在全球III期试验达到了主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f33d18355468)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947727, encodeId=0fd6194e72788, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=多发性骨髓瘤治疗：Kyprolis与Darzalex的组合在III期试验中达到了主要终点, objectType=article, longId=179450, objectId=b45b1e9450d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b45b1e9450d9, replyNumber=0, likeNumber=67, createdTime=2020-01-31, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b45b1e9450d9, moduleTitle=多发性骨髓瘤治疗：Kyprolis与Darzalex的组合在III期试验中达到了主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b45b1e9450d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947716, encodeId=c7bf194e71680, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=子宫内膜异位症相关疼痛：GnRH受体拮抗剂linzagolix的II期试验取得成功, objectType=article, longId=165448, objectId=640116544883, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=640116544883, replyNumber=0, likeNumber=64, createdTime=2019-12-15, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=640116544883, moduleTitle=子宫内膜异位症相关疼痛：GnRH受体拮抗剂linzagolix的II期试验取得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=640116544883)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947728, encodeId=b6cf194e7287e, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=Enhanze药物输送技术：评估固定剂量皮下注射帕妥珠单抗和曲妥珠单抗的III期试验取得阳性结果, objectType=article, longId=179522, objectId=8c931e952273, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c931e952273, replyNumber=0, likeNumber=81, createdTime=2020-08-07, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c931e952273, moduleTitle=Enhanze药物输送技术：评估固定剂量皮下注射帕妥珠单抗和曲妥珠单抗的III期试验取得阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c931e952273)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947725, encodeId=682c194e7257f, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=JAK抑制剂Olumiant联合治疗特应性皮炎的III期试验达到主要终点, objectType=article, longId=178209, objectId=6ad01e8209da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ad01e8209da, replyNumber=0, likeNumber=60, createdTime=2020-02-14, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ad01e8209da, moduleTitle=JAK抑制剂Olumiant联合治疗特应性皮炎的III期试验达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ad01e8209da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947720, encodeId=d013194e720c9, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=枸橼酸西地那非治疗新生儿持续性肺动脉高压的III期试验结果, objectType=article, longId=174500, objectId=3cc31e45003d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3cc31e45003d, replyNumber=0, likeNumber=70, createdTime=2019-11-25, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3cc31e45003d, moduleTitle=枸橼酸西地那非治疗新生儿持续性肺动脉高压的III期试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3cc31e45003d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947721, encodeId=9d8b194e72194, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=不可切除或转移性晚期黑色素瘤的治疗或再迎新药：评估masitinib的III期试验, objectType=article, longId=176830, objectId=36111e683054, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36111e683054, replyNumber=0, likeNumber=61, createdTime=2019-12-25, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36111e683054, moduleTitle=不可切除或转移性晚期黑色素瘤的治疗或再迎新药：评估masitinib的III期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36111e683054)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947719, encodeId=5bb7194e71906, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=肺动脉高压治疗新药：Sotatercept的PULSAR II期试验已完成患者入组, objectType=article, longId=174333, objectId=d0051e433350, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d0051e433350, replyNumber=0, likeNumber=80, createdTime=2019-11-17, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d0051e433350, moduleTitle=肺动脉高压治疗新药：Sotatercept的PULSAR II期试验已完成患者入组, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d0051e433350)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947722, encodeId=7a0d194e72264, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=Saroglitazar Magnesium治疗2型糖尿病的III期试验取得积极结果, objectType=article, longId=176832, objectId=b5881e683297, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b5881e683297, replyNumber=0, likeNumber=82, createdTime=2020-06-28, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b5881e683297, moduleTitle=Saroglitazar Magnesium治疗2型糖尿病的III期试验取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b5881e683297)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947724, encodeId=ad4f194e724a4, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=赛诺菲白细胞介素4/13单抗Dupixent在严重特应性皮炎儿童患者的III期试验成功, objectType=article, longId=177128, objectId=d21f1e7128a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d21f1e7128a2, replyNumber=0, likeNumber=75, createdTime=2019-12-30, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d21f1e7128a2, moduleTitle=赛诺菲白细胞介素4/13单抗Dupixent在严重特应性皮炎儿童患者的III期试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d21f1e7128a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

II期试验

2020-05-29

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

Novavax启动COVID-19候选疫苗NVX-CoV2373的I / II期试验

2020-07-30

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

ACE-083治疗夏科-马里-图思病（CMT）的II期试验遭遇滑铁卢

2020-04-21

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

VEGFR抑制剂Cediranib联合PARP抑制剂Lynparza治疗铂敏感复发性卵巢癌的III期试验失败

2020-08-31

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

ChemoCentryx的Avacopan补体5a受体抑制剂治疗血管炎的III期试验达到了主要终点

2020-01-30

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

2020年ASCO-SITC：Ilixadencel治疗肾癌的II期试验的数据更新

2021-01-15

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

诺华的CD20单抗Arzerra治疗多发性硬化症的两项III期试验成功

2020-04-07

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

Biogen的aducanumab治疗阿尔茨海默氏病符合III期试验终点

2019-12-17

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

第68届ASTMH年会：登革热候选疫苗关键III期试验的18个月数据

2020-07-05

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

J Clin Oncol：III期试验：培美曲塞联合贝伐单抗作为NSCLC患者的维持疗法的有效性和安全性

2020-01-26

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

Rivipansel治疗镰状细胞病的III期试验：未达到主要终点

2019-09-27

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

2019 ESMO亚洲大会：国产曲妥珠单抗仿制药HLX02治疗乳腺癌在全球III期试验达到了主要终点

2020-06-02

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

多发性骨髓瘤治疗：Kyprolis与Darzalex的组合在III期试验中达到了主要终点

2020-01-31

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

子宫内膜异位症相关疼痛：GnRH受体拮抗剂linzagolix的II期试验取得成功

2019-12-15

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

Enhanze药物输送技术：评估固定剂量皮下注射帕妥珠单抗和曲妥珠单抗的III期试验取得阳性结果

2020-08-07

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

JAK抑制剂Olumiant联合治疗特应性皮炎的III期试验达到主要终点

2020-02-14

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

枸橼酸西地那非治疗新生儿持续性肺动脉高压的III期试验结果

2019-11-25

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

不可切除或转移性晚期黑色素瘤的治疗或再迎新药：评估masitinib的III期试验

2019-12-25

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

肺动脉高压治疗新药：Sotatercept的PULSAR II期试验已完成患者入组

2019-11-17

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

Saroglitazar Magnesium治疗2型糖尿病的III期试验取得积极结果

2020-06-28

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

赛诺菲白细胞介素4/13单抗Dupixent在严重特应性皮炎儿童患者的III期试验成功

2019-12-30

科室
- - 订阅+
  - 更多科室
工具
服务